A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:

• A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.

A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...

Panagiotis Xaplanteris reports on the ISCHEMIA-CKD EXTEND trial results - clinical outcomes at 5 years of follow-up, which were presented during the ESC 2022 congress in Barcelona.

This EIJ image highlights a new device designed to enhance the safety and efficiency of ViV TAVI procedures, particularly TAV-in-TAV, by reducing attempts to cross the valve and preventing guidewire misnavigation, thereby minimizing complications and procedure time.

Elad Asher provides his take on the ULTIMATE-DAPT Trial results which Gregg W Stone presented at ACC.24 in Atlanta.

The SPYRAL HTN-OFF MED Pivotal trial is a sham controlled randomized study examining the efficacy and safety of renal artery denervation (RDN) compared to a sham group, and the primary endpoint was the reduction in the blood pressure of subjects with uncontrolled hypertension not on antihypertensive...

The POPular TAVI trial is an open label randomized study designed to evaluate oral anticoagulation (OAC) alone compared with OAC plus clopidogrel for 3 months in patients undergoing transcatheter aortic valve replacement (TAVR) with a long-term indication for oral anticoagulation. Those who had undergone percutaneous revascularization...

Thirty years ago, the interventional cardiology field was transformed with the emergence of a new access site – the radial artery was used for coronary angioplasty and stent implantation for the first time on 14 August 1992.

The results of the SCOPE I trial were presented at TCT 2019 in San Francisco by Jonas Lanz, Bern University Hospital. Read the analysis by Fabien Praz.

Pamela Gatto provides her take on the Intrepid Global Pilot Study which was presented by Renuka Jain at TCT Congress 2022.

Nicola Ryan provides her take on this investigator initiated, multicentre, randomised, blinded, sham controlled trial compares clinical outcomes of QFR versus angiography guided strategies for the treatment of non-critical lesions in patients with stable or unstable angina or MI at least 72 hours prior to screening....

Lucas Lauder and Felix Mahfoud provide a summary of the ESC Guidelines on elevated blood pressure and hypertension presented by John William McEvoy and Rhian Touyz at ESC Congress 2024 in London.

Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.

Nicola Ryan provides her take on the results of TAILORED-CHIP presented by Duk-Woo Park at the ESC Congress 2025 in Madrid.

Alessandro Sticchi and Luigi Biasco provide their take on the 1-year results of the CLASP TR study which were presented by Dr Adan Greenbaum, co-director of the Emory Structural Heart and Valve Center (Atlanta, GA) during the 2022 American College of Cardiology annual Congress held in Washington D.C.

Following the Hot Line session of the ESC Congress 2021 presented by George Dangas (New-York, USA), Daniele Giacoppo offers us a condensed version of this study.